Conditional relative survival among patients with chronic lymphocytic leukaemia: A population‐based study in the Netherlands

Lina van der Straten(Erasmus MC), Avinash G. Dinmohamed(Erasmus MC), Mark‐David Levin(Albert Schweitzer Ziekenhuis), Otto Visser(Netherlands Comprehensive Cancer Organisation), Arnon P. Kater(Sanford Burnham Prebys Medical Discovery Institute), Eduardus F. M. Posthuma(Leiden University Medical Center), Jeanette K. Doorduijn(Université Paris Cité)
eJHaem
December 20, 2021
10.1002/jha2.368
Cited by 9

Related Papers

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568
Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non–Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis
|Journal of Clinical Oncology|2010|478
Early-stage lung cancer in elderly patients: A population-based study of changes in treatment patterns and survival in the Netherlands
|Annals of Oncology|2012|173